- Home
- NRGV vs CSTL Comparison
NRGV vs CSTL Comparison
Compare NRGV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRGV | CSTL |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.5M | 661.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NRGV | CSTL |
|---|---|---|
| Price | $4.88 | $39.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.75 | ★ $42.83 |
| AVG Volume (30 Days) | ★ 3.2M | 364.8K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $83,836,000.00 | ★ $343,530,000.00 |
| Revenue This Year | $322.22 | $1.69 |
| Revenue Next Year | $29.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $0.60 | $14.59 |
| 52 Week High | $5.56 | $42.18 |
Technical Indicators
Market Signals| Indicator | NRGV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 61.26 |
| Support Level | $4.30 | $37.76 |
| Resistance Level | $5.11 | $42.18 |
| Average True Range (ATR) | 0.53 | 1.22 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 50.95 | 52.48 |
Price Performance
Historical ComparisonAbout NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.